Use of argatroban during percutaneous coronary interventions in patients with heparin-lnduced thrombocytopenia

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 2 SUPPL. 1, 1999, Pages 57-60

  Matthai Jr , William H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Argatroban; Coronary angioplasty; Heparin induced thrombocytopenia; Thrombosis

Indexed keywords

ABCIXIMAB; ARGATROBAN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY DISEASE; DRUG EVALUATION; HEPARIN; HUMANS; PIPECOLIC ACIDS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0344947891     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relationship between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-1065
2. Detre KM, Holmes DR, Holubkov R, et al. Incidence and consequences of periprocedural occlusion. Circulation 1990;82: 739-750
3. Kuntz RE, Piana R, Pomerantz RM, et al. Changing incidence and management of abrupt closure following coronary intervention in the new device era. Cathet Cardiovasc Diagn 1992;27:183-190
4. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992;19:926-935
5. de Feyter PJ, van den Brand M, Jaarman G, et al. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Frequency, prediction, clinical course, management, and follow-up. Circulation 1991;83:927-936
6. EPILOG Investigators. Effect of the platelet glycoprotein IIb/IIIa receptor inhibitor abeiximab with lower heparin dosages on ischemic complications of percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696
7. Laskey MAL, Deutsch E, Hirshfeld, Jr JW, et al. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus. Am J Cardiol 1990;65:179-182
8. Weitz JL, Hudoba M, Massel D, Maraganore J, Hirsh J. Clotbound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin II-independent inhibitors. J Clin Invest 1990;86:385-391
9. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-145
10. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-1935
11. Matthai WH, Kurnik PB, Grob WC, Untereker WJ, Siegel J. Antithrombin actvity during the period of percutaneous coronary revascularization: Relation to heparin use, thrombotic complications and restenosis. J Am Coll Cardiol, in press.
12. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-507
13. Boshkov LK, Warkentin TE, Hayward CPM, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: Clinical and laboratory studies. Br J Haematol 1993;84:322-328
14. Clowes AW, Schwartz SM. Endothelial regeneration. V. Inhibition of endothelial regrowth in arteries of rat and rabbit. Lab Invest 1983;49:569-575
15. Lewis BE, Matthai W, Grassman ED, et al. Results of phase 2/3 trial of argatrohan anticoagulation during PTCA of patients with heparin-induced thrombocytopenia (HIT). Circulation 1997;96:1-217
16. Malenka DJ. Indications, practice, and procedural outcomes of percutaneous transluminal coronary angioplasty in northern New England in the early 1990s. The Northern New England Cardiovascular Disease Study Group. Am J Cardiol 1996; 78:260-265